Cell Line News and Research

RSS

Researchers identify glycolipid that blocks infection with SARS-CoV-2 and RSV

7DW8-5, a glycolipid that utilizes the body's non-specific immune response to quickly combat viral infections, including COVID-19 in vivo.

11 Jul 2023

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA.

From Sphere Fluidics 6 Jul 2023

Researchers uncover the role of glutaminase 2 in glucose homeostasis

Glutaminase 2 (GLS2) is a master regulator of glutaminolysis. GLS2 converts glutamine to glutamate, thereby playing a role in cellular energy production. GLS2 is abundant in the liver, and is also found in pancreatic β-cells. However, the role of GLS2 in pancreatic islets – in which both ɑ- and β- cells are present – associated with glucose metabolism is currently unknown.

5 Jul 2023

CRISPR/Cas9-based screening identifies potential therapies for non-alcoholic fatty liver disease

Activation of the NRF2 transcription factor shows promise as a potential treatment approach for non-alcoholic fatty liver disease (NAFLD), a condition associated with oxidative stress and liver damage. By screening FDA-approved drugs, researchers identified six compounds that enhanced NRF2 activity and demonstrated protective effects against oxidative stress and lipid accumulation.

3 Jul 2023

Novel biomaterials approach reveals how mechanical forces shape T cell fate

The successful campaign of adoptive T cell therapies, a type of immunotherapy in which immune T cells are collected from a patient, enhanced outside of the body, and reinfused back into the same patient, especially against blood cancers is well under way.

26 Jun 2023

BU study reveals crucial signaling pathway that drives head and neck cancers

Despite advances in defining the genomic characteristics of head and neck cancers, these malignancies continue to rank among the deadliest cancers with few targeted therapies available.

23 Jun 2023

Study reveals contrasting effects of sucralose on insulin and glucose control

Sucralose, a commonly used artificial sweetener, has contrasting effects on insulin secretion and glucose homeostasis. While bolus administration of sucralose enhances insulin secretion and decreases glucose levels, long-term consumption exacerbates insulin resistance and glucose intolerance, particularly in combination with a high-fat diet. The study highlights the involvement of the T1R3-ERK1/2 pathway in sucralose-induced insulin resistance in the liver.

22 Jun 2023

Researchers take promising step forward in the battle against HIV

A multi-institutional research group led by researchers from Tokyo Medical and Dental University (TMDU) has made a significant and promising step forward in our ability to treat human immunodeficiency virus type 1 (HIV-1), the virus underlying acquired immunodeficiency syndrome (AIDS).

21 Jun 2023

3D-printed vaginal ovules offer promising treatment for endometriosis

3D-printed vaginal ovules offer controlled release and targeted treatment, showing promise for conditions like endometriosis.

20 Jun 2023

Catalent expands OneBio® suite for integrated development, manufacturing and supply across biologic modalities

Catalen today announced that it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies, and mRNA.

From Catalent 16 Jun 2023

Meat-free minerals: the mineral content, bioaccessibility, and bioavailability of iron and zinc vegetarian and vegan burgers

Researchers compared the mineral content and absorption of plant-based meat-free (vegan and vegetarian) burgers and beef burgers.

15 Jun 2023

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

13 Jun 2023

H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development

H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization.

From H.E.L Group 8 Jun 2023

New strategy to grow and measure how tumor organoids respond to therapy

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a new method to bioprint miniature tumor organoids that are designed to mimic the function and architecture of real tumors. The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail, which can help researchers identify personalized treatments for people with rare or hard-to-treat cancers.

7 Jun 2023

CBD and EPA cream: Dynamic duo for youthful skin

A recent study examines the anti-aging potential of a new cream formulation that contains CBD and EPA.

6 Jun 2023

ISSCR proposes new guidelines for using stem cells in research

The International Society for Stem Cell Research (ISSCR) today released the ISSCR Standards for Human Stem Cell Use in Research, an international collaboration aimed at enhancing rigor in preclinical research and ultimately strengthening the pipeline of therapies for patients.

6 Jun 2023

RNA regulatory mechanism could be targeted to slow AD progression mediated by stress granules

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 10, entitled, "Stress granules sequester Alzheimer's disease-associated gene transcripts and regulate disease-related neuronal proteostasis."

1 Jun 2023

Lipid-degrading enzyme, fatty acid amide hydrolase is a predictor of long-term survival in patients with breast cancer

Scientists have identified a lipid-degrading enzyme as a prognostic biomarker for luminal breast cancer.

31 May 2023

Novel assay for identifying individuals with synucleinopathies using serum samples

Synucleinopathies are a group of neurodegenerative diseases caused by the abnormal accumulation α-synuclein, a protein normally found in the brain and neurons. Incorrect folding of α-synuclein leads to formation of 'seeds', which attract more α-synuclein proteins to form larger clumps.

29 May 2023

Scientists unveil a metabolic Achilles' heel in pancreatic cancer

Research unveils the significance of uridine as a metabolic fuel in pancreatic ductal adenocarcinoma (PDA) cells under glucose-deprived conditions. Uridine utilization, mediated by uridine phosphorylase 1 (UPP1), supports redox balance, survival, and proliferation in PDA, highlighting its potential as a novel therapeutic target in the treatment of this resistant cancer.

23 May 2023